Headline weight-loss numbers compare body weight reduction. Body composition research compares what fraction of that loss was fat, what fraction was lean tissue, and where the fat came off (visceral vs subcutaneous). For tirzepatide vs semaglutide, the body composition picture sharpens the comparison significantly.
The DEXA scan data
From phase 3 trials with body composition sub-analyses:
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Total body weight loss | 14.9% | 22.5% |
| Fat mass reduction | ~10.5% | ~18% |
| Lean mass reduction | ~4.4% | ~4.5% |
| Fat-to-lean loss ratio | ~70/30 | ~80/20 |
The interesting pattern
Note that absolute lean mass loss is similar between the two compounds — approximately 4.4% versus 4.5%. The difference in total body weight loss comes almost entirely from differential fat-mass reduction. Tirzepatide loses more fat without losing more lean tissue.
This is the mechanism implication of GIP receptor activation. The GIP arm appears to favour adipose tissue metabolism shifts — the compound preferentially mobilises fat mass while the lean mass loss profile mirrors what semaglutide produces.
Visceral vs subcutaneous fat
Visceral adipose tissue (VAT) and subcutaneous fat respond differently to incretin agonist therapy. Research with imaging-based VAT measurement shows:
- Semaglutide: ~25% VAT reduction over 68 weeks
- Tirzepatide: ~33-35% VAT reduction over 72 weeks
Both preferentially reduce VAT relative to subcutaneous fat — a metabolically favourable shift. Tirzepatide’s larger reduction tracks with its overall larger weight loss.
Liver fat — separate endpoint
Hepatic lipid content (steatosis) responds to incretin agonist therapy independent of total weight loss:
- Semaglutide: ~30% reduction in liver fat fraction
- Tirzepatide: ~38-44% reduction in liver fat fraction
The liver fat reduction is partly direct (incretin effects on hepatic lipid handling) and partly indirect (overall fat mass reduction). Both compounds show clinically meaningful improvements in liver outcome research.
The duration adjustment
Semaglutide trial is 68 weeks; tirzepatide is 72 weeks. Adjusted for duration, the per-week body composition shift is:
- Semaglutide: ~0.15% fat mass/week
- Tirzepatide: ~0.25% fat mass/week
Tirzepatide produces fat mass loss approximately 1.6x faster than semaglutide on a per-week basis.
What this means for body composition research
For research protocols where the primary endpoint is fat mass reduction (rather than total body weight):
- Tirzepatide is the dominant compound for fat-loss-specific endpoints
- Semaglutide remains useful for longer-duration studies and as a reference compound (more published data)
- Lean mass preservation is similar between the two — neither is dramatically better for lean retention
Resistance training interaction
Combined research that adds resistance training to either compound shifts the fat-to-lean loss ratio further toward fat:
- GLP-1 + resistance training: fat-to-lean ratio shifts toward 85/15 versus 70/30 without training
- Effect is similar with either compound
For body-composition optimisation research, the training variable matters as much as compound selection.
SURPASS-2 head-to-head
The SURPASS-2 trial (Frias et al., NEJM 2021) directly compared tirzepatide and semaglutide in adults with type 2 diabetes. At equivalent positions (1mg semaglutide vs tirzepatide arms), tirzepatide produced approximately 2x the weight loss across all three tirzepatide doses tested. Body composition sub-analyses confirmed the differential was driven by fat mass.
See our head-to-head trial article for full SURPASS-2 detail.
For research selection
- Maximum fat mass endpoint → Tirzepatide
- Established long-duration data → Semaglutide
- VAT-specific research → Tirzepatide (larger reduction)
- Liver fat research → Tirzepatide (larger reduction)
- Lean preservation research → Either (similar profile)
Chempeptides supplies both compounds — see the catalogue and our deeper tirzepatide mechanism article and semaglutide mechanism article.
For laboratory research use only. Body composition data summarised from published peer-reviewed research.